CBU
BMRN icon

CIBC Bancorp USA’s BioMarin Pharmaceuticals BMRN Stock Holding History

CIBC Bancorp USA’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-207,796
Closed -$11.7M – 1946
2026
Q1 		$11.7M Buy
+207,796
New +$12.1M 0.02% 459
2025
Q3 		$372K Buy
+6,876
New +$393K ﹤0.01% 996

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

CIBC Bancorp USA's BMRN Position: Q2 2026 in Review

CIBC Bancorp USA sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 207,796 shares — an estimated $11.7M sold.

CIBC Bancorp USA first reported a position in BMRN in Q3 2025 and held it in 2 quarters. The position peaked at $11.7M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • CIBC Bancorp USA reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • CIBC Bancorp USA sold 207,796 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $11.7M.
  • CIBC Bancorp USA first reported a position in BioMarin Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • CIBC Bancorp USA's BioMarin Pharmaceuticals position peaked at $11.7M in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.